Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Covidien approved to use new reactor for medical isotope production

Covidien approved to use new reactor for medical isotope production

12th March 2010

Covidien has received regulatory clearance from the Food and Drug Administration (FDA) to use materials produced by the Maria Research Reactor in Poland in creating medical isotopes.

The medical solutions firm will now be able to use molybdenum 99 (Mo 99) produced by the facility to create generators for Technetium 99m, a vital component of nuclear medicine diagnostic and functional studies.

This supply agreement between Covidien and the Maria facility was confirmed last month, with the Mo 99 supplied by the reactor estimated to aid more than one million patients worldwide within six months.

Covidien’s president of pharmaceuticals Timothy Wright welcomed the speed of the FDA’s approval, stating that the development will be of benefit to patients.

He said: “Their actions are great news for patients who may have been facing longer delays in receiving critical nuclear medicine diagnostic procedures.”

The agreement with the Maria Research Reactor has already been hailed by Covidien as an historic move, as it is the first time in several decades that a new reactor has become part of the global supply chain for medical isotopes.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.